首页> 美国卫生研究院文献>BMC Medical Informatics and Decision Making >A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children
【2h】

A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children

机译:一种贝叶斯决策支持工具用于成人和儿童中华法林的有效剂量个性化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundWarfarin is the most widely prescribed anticoagulant for the prevention and treatment of thromboembolic events. Although highly effective, the use of warfarin is limited by a narrow therapeutic range combined with a more than ten-fold difference in the dose required for adequate anticoagulation in adults. An optimal dose that leads to a favourable balance between the wanted antithrombotic effect and the risk of bleeding as measured by the prothrombin time International Normalised Ratio (INR) must be found for each patient. A model describing the time-course of the INR response can be used to aid dose selection before starting therapy (a priori dose prediction) and after therapy has been initiated (a posteriori dose revision).
机译:背景技术华法林是预防和治疗血栓栓塞事件的最广泛处方的抗凝剂。尽管非常有效,但华法林的使用受到狭窄的治疗范围的限制,并且成人中充分抗凝所需的剂量差异超过十倍。必须为每位患者找到一个最佳剂量,该剂量可在所需的抗血栓形成作用和出血风险之间找到有利的平衡,凝血酶原时间以国际标准化比率(INR)衡量。在开始治疗之前(先验剂量预测)和开始治疗之后(后验剂量修订),可以使用描述INR反应时程的模型来辅助剂量选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号